Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Connect Biopharma Holdings Limited - Ordinary Shares (NQ:CNTB)

2.637 -0.183 (-6.49%)
Streaming Delayed Price Updated: 12:54 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Connect Biopharma Holdings Limited - Ordinary Shares

< Previous 1 2 3 Next >
News headline image
Connect Biopharma to Present at the 8th Annual Evercore Healthcare Conference
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma and Bimergen Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
News headline image
Connect Biopharma Reports Third Quarter 2025 Financial Results and Provides Business Update
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Join Connect Biopharma's Exclusive Live Investor Webinar and Q&A Session on November 3
Via ACCESS Newswire
News headline image
Connect Biopharma Presents Data Supporting Rademikibart at the European Respiratory Society Congress 2025
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Completes Termination of its American Depositary Receipt Program and Directly Lists its Ordinary Shares on Nasdaq
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma to Present at Two Upcoming Investor Conferences in September
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma’s Exclusive Licensee in China, Simcere Pharmaceutical, Announced Submission of its New Drug Application for Rademikibart for the Treatment of Atopic Dermatitis in China
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma to Present at Two Upcoming Investor Conferences in June
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Announces Multiple Presentations at the American Thoracic Society (ATS) 2025 International Conference
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Bullfrog AI and Connect Biopharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
News headline image
Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma to Present at Two Upcoming Investor Conferences
From Connect Biopharma Holdings Limited
Via GlobeNewswire
David Szekeres, President of Connect Biopharma Holdings Limited (NASDAQ: CNTB), to Present at NobleCon20
Via Investor Brand Network
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.